Regulatory considerations of a growing pharmaceutical company: a UK/US comparison of the generics industry

AdobeStock_386873785

Generics must demonstrate equivalence to the originator product to gain regulatory approval and market entry. There is a large market for generics that is predicted to continue to grow. The individual price of generics is lower than the originator, nevertheless manufacturers can avoid large development costs to bring generics to ...

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to TOPRA members and registered users.

If you are a TOPRA member, or have already registered for limited free access, log in now (Option 1 below).

Not yet a member? You can either join TOPRA (Option 2 below) or register to view limited content for free (Option 3 below).

1. LOGIN

Already a TOPRA member?

Log in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

Already registered for free content?

If you are not a TOPRA member but have already created an account to access limited free content, log in here using your registered user email and password.

Login

2. JOIN TOPRA

Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2026 for the exclusive rate of £230.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 30 September 2025

Become a member

3. REGISTER FOR FREE

Want free access to selected content?

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account